Neurological SciencesPub Date : 2025-07-01Epub Date: 2025-03-11DOI: 10.1007/s10072-025-08077-y
Simona Portaro, Angelo Alito, Giulia Leonardi, Nicola Marotta, Adriana Tisano, Daniele Bruschetta, Umile Giuseppe Longo, Antonio Ammendolia, Demetrio Milardi, Alessandro de Sire
{"title":"Efficacy of neuromodulation and rehabilitation approaches on pain relief in patients with spinal cord injury: a systematic review and meta-analysis.","authors":"Simona Portaro, Angelo Alito, Giulia Leonardi, Nicola Marotta, Adriana Tisano, Daniele Bruschetta, Umile Giuseppe Longo, Antonio Ammendolia, Demetrio Milardi, Alessandro de Sire","doi":"10.1007/s10072-025-08077-y","DOIUrl":"10.1007/s10072-025-08077-y","url":null,"abstract":"<p><strong>Introduction: </strong>Spinal cord injury (SCI) is a debilitating neurological condition that causes physical dependency, psychological distress, and financial burden. Pain is a common consequence of SCI, significantly impacting quality of life. Effective pain management in SCI is challenging and requires multifaceted approaches. Among rehabilitation methods, non-invasive brain stimulation techniques such as repetitive transcranial magnetic stimulation (rTMS), theta burst stimulation (TBS), transcranial direct current stimulation (tDCS), transcutaneous electrical nerve stimulation (TENS), and virtual reality (VR) have been explored. This study aims to evaluate the efficacy of rehabilitation and non-invasive brain stimulation techniques on pain relief in SCI patients.</p><p><strong>Methods: </strong>A systematic review of the literature was conducted using PubMed, Scopus, and ScienceDirect with the formula (\"spinal cord injury\") AND (\"pain\"). Risk of bias was assessed using the Cochrane Risk of Bias Tool.</p><p><strong>Results: </strong>Sixteen studies involving 319 patients were included. Patients in the control groups received: rTMS in seven trials, tDCS in seven trials, TBS in one trial, and TENS combined with VR in one trial. The trials analyzed were of poor methodological quality, characterized by small sample sizes, weak power analyses, varying clinical scores, and non-comparable follow-up periods. No major complications or serious adverse events were reported.</p><p><strong>Conclusion: </strong>Results were inconsistent, with no solid evidence supporting the superiority of rehabilitation techniques over comparator treatments. However, the favorable safety profile and positive outcomes in some measures suggest potential benefits for pain management and quality of life. Further studies are necessary to better understand SCI-related pain and optimize treatment strategies.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":"2995-3020"},"PeriodicalIF":2.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dan Li, Na Sun, Hongbo Wu, Xueying Wang, Yongjing Shi, Lin Yang, Shaoping Huang, Kun Zhang, Changhong Yang
{"title":"Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients.","authors":"Dan Li, Na Sun, Hongbo Wu, Xueying Wang, Yongjing Shi, Lin Yang, Shaoping Huang, Kun Zhang, Changhong Yang","doi":"10.1007/s10072-025-08267-8","DOIUrl":"https://doi.org/10.1007/s10072-025-08267-8","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study investigated the predictive value of clinical characteristics and cerebrospinal fluid (CSF) metabolites for nusinersen efficacy in children with spinal muscular atrophy (SMA).</p><p><strong>Methods: </strong>In this study, clinical data and CSF samples were collected. We used liquid chromatography-tandem mass spectrometry to analyze CSF metabolites from 42 patients with type II and type III SMA.</p><p><strong>Results: </strong>Although clinical indicators, such as age at treatment initiation and disease duration, did not predict the clinical efficacy of nusinersen, we identified 47 differentially expressed metabolites between effective- and ineffective-treatment patients with type II disease and 109 metabolites in patients with type III disease. Additionally, KEGG-enriched pathway analysis revealed differences in several pathways between the effective- and ineffective-treatment groups for both types II and III. N-myristoyl arginine and 1,1,1,2,2,2-Pentafluoro-7-phenylheptan-3-one were negatively associated with Hammersmith Functional Motor Scale Expanded changes in patients with type III and type III SMA. Furthermore, multivariate receiver operating characteristic curve analysis indicated that differential metabolites have some accuracy in predicting SMA treatment efficacy.</p><p><strong>Conclusion: </strong>This study identified CSF metabolites that are predictive of nusinersen efficacy. The results of this study may guide the development of adjunctive therapies for improving the efficacy of nusinersen.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yajun Jing, Peisen Yao, Honglin Zhu, Lianghong Yu, Yuanxiang Lin, Dezhi Kang
{"title":"The Role and Mechanisms of G protein-coupled receptors in Parkinson's disease.","authors":"Yajun Jing, Peisen Yao, Honglin Zhu, Lianghong Yu, Yuanxiang Lin, Dezhi Kang","doi":"10.1007/s10072-025-08260-1","DOIUrl":"https://doi.org/10.1007/s10072-025-08260-1","url":null,"abstract":"<p><p>This comprehensive review meticulously examines the pivotal and multifaceted role of G protein-coupled receptors (GPCRs) in the complex pathogenesis of Parkinson's disease (PD), a neurodegenerative disorder that profoundly impacts motor control and cognitive function. Initially, we introduce the fundamental concepts of GPCRs, delving into their intricate structures and diverse functions within the nervous system, highlighting their importance as key players in cellular communication and signal transduction. Following this foundational overview, we thoroughly analyze specific GPCRs that have been closely associated with the onset and progression of PD, exploring the intricate mechanisms by which they influence disease progression through the nuanced regulation of neurotransmitter release, complex signaling pathways, and crucial aspects of cell survival. Furthermore, we engage in a detailed discussion regarding the promising prospects of GPCRs as potential therapeutic targets for intervention in PD, emphasizing the significance of recent groundbreaking research findings that shed light on the therapeutic implications of modulating GPCR activity. Finally, drawing upon the latest advancements in research, we propose insightful directions for future studies, as well as a thoughtful consideration of the myriad challenges that lie ahead in this dynamic and rapidly evolving field of study, which holds the potential to enhance our understanding of PD and pave the way for innovative treatment strategies.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: A new swallowing supplement for dysphagia in patients with Parkinson's disease.","authors":"Eungseok Oh, Sungju Jee, Bum Keun Kim, Jung Seon Lee, Kanghee Cho, Soyoung Ahn","doi":"10.1007/s10072-025-08285-6","DOIUrl":"https://doi.org/10.1007/s10072-025-08285-6","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the editor, regarding \"Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events\" recently published by Boy and colleagues.","authors":"Senta Frol, Matjaž Sever","doi":"10.1007/s10072-025-08288-3","DOIUrl":"https://doi.org/10.1007/s10072-025-08288-3","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chronic inflammatory demyelinating polyneuropathy in end-stage renal disease patients: a case series study.","authors":"Yize Li, Yakun Wu, Zhenyu Li, Jieyu Li, Ping Li, Zhiying Xie, Yiming Zheng, Jianwen Deng, He Lv, Zhaoxia Wang, Yun Yuan, Lingchao Meng","doi":"10.1007/s10072-025-08278-5","DOIUrl":"https://doi.org/10.1007/s10072-025-08278-5","url":null,"abstract":"<p><strong>Objectives: </strong>The occurrence of chronic inflammatory demyelinating polyneuropathy (CIDP) in patients with end-stage renal disease (ESRD) has been rarely studied. This study was intended to explore the clinical, electrophysiological and neuropathological features of six patients with CIDP and ESRD.</p><p><strong>Methods: </strong>The medical records collected in Peking University First Hospital between 2021 and 2024 were reviewed before six patients were identified who had developed CIDP with ESRD. The data on their clinical features, electrophysiological tests, nerve ultrasound, laboratory examinations and sural biopsies was retrieved.</p><p><strong>Results: </strong>All the six patients were males ages 35 to 63. Before and after dialysis, all these patients presented with varying degrees of limb sensory impairment and weakness, and reduced or absent tendon reflexes. Albuminocytologic dissociation of cerebrospinal fluid was observed in all of them. Nerve conduction studies identified the demyelinating features while nerve ultrasound showed nerve enlargement of upper limbs. Sural nerve biopsies showed mild to moderate decreases of myelinated nerve fiber density, with differences between different nerve fascicles. Thin myelinated fibers were seen, without onion bulb-like structure. Varying degrees of axonal degeneration with regeneration were identified in some of these patients. Immunotherapy was effective in all these patients.</p><p><strong>Conclusions: </strong>The diagnosis of CIDP should be considered if an ESRD patient develops progressive demyelinating neuropathy. Immune therapy has shown clinical efficacy despite the underlying mechanisms that remain poorly understood.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Frequency of anti-GQ1b IgG antibody in miller fisher syndrome: a Chinese single center study.","authors":"Pengfei Shao, Wenhui Wu, Xin Zhang, Haifeng Chen, Yun Xu, Qing Ye","doi":"10.1007/s10072-025-08290-9","DOIUrl":"https://doi.org/10.1007/s10072-025-08290-9","url":null,"abstract":"<p><strong>Background: </strong>The anti-GQ1b IgG antibody has been traditionally regarded as a sensitive marker for Miller Fisher syndrome (MFS). Nevertheless, its prevalence might vary across regions and could be affected by the coronavirus disease 2019 (COVID-19) pandemic. This retrospective study was designed to evaluate the positivity rate of the anti-GQ1b IgG antibody among MFS patients admitted to a single Chinese center and to examine the influence of the COVID-19 pandemic thereon.</p><p><strong>Methods: </strong>We retrospectively analyzed the medical records of patients diagnosed with MFS and admitted to our hospital from January 2018 to March 2024. Anti-ganglioside antibodies were tested in acute-phase serum samples using enzyme-linked immunosorbent assay (ELISA) or immune-dot assays.</p><p><strong>Results: </strong>Of the 72 patients admitted for MFS, 51 were tested for ganglioside antibodies. Only 9 (17.65%) of the tested patients were found to have the anti-GQ1b IgG antibody. The positivity rate of the antibody was comparable between patients with the complete form of MFS and those with the incomplete form (17.39% vs. 17.86%, P = 0.965). Additionally, the positivity rate was significantly lower during and after the COVID-19 pandemic compared to before the pandemic (8.33% vs. 40.00%, P = 0.007).</p><p><strong>Conclusions: </strong>The anti-GQ1b IgG antibody is infrequently detected in MFS patients admitted to our center, especially during and after the COVID-19 pandemic. Future prospective multicenter investigations are expected to contribute significantly to the further clarification of the prevalence of anti-GQ1b IgG antibody in MFS patients across various regions of China.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serum sirtuin 3 levels and multimodal abnormalities in brain structure and function in Parkinson's disease patients with depression.","authors":"Mahnoor Sultana, Ayesha Parvaiz Malik, Javed Iqbal, Brijesh Sathian","doi":"10.1007/s10072-025-08289-2","DOIUrl":"https://doi.org/10.1007/s10072-025-08289-2","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}